The IPO Buzz: Jyong Biotech (MENS) Prices IPO at $7.50 – Low End – & Soars on NASDAQ

Jyong Biotech Ltd. (MENS), a Taiwan-based biotech developing drugs to treat benign prostate hyperplasia and to prevent prostate cancer, priced its IPO at $7.50 – the low end of its range – and sold 2.7 million shares – the number of shares in the prospectus – to raise $20.0 million on Monday night, June 16, 2025. Jyong Biotech’s stock doubled its IPO price - scoring a moonshot when it op..

Read more June 17, 2025

IPO Calendar

Company Symbol proposed Lead Managers Shares (Millions) Price Low Price High Est. $ Volume Expected to Trade SCOOP Rating Rating Change
Jyong Biotech Ltd. (Revived IPO) MENS Joseph Stone Capital LLC 2.7 7.50 7.50 $ 20.0 mil 6/17/2025 Priced S/O S/O
Axiom Intelligence Acquisition Corp. I AXINU Cohen & Company Capital Markets/Seaport Global Securities 17.5 10.00 10.00 $ 175.0 mil 6/18/2025 Priced S/O S/O
Caris Life Sciences, Inc. CAI BofA Securities/J.P. Morgan/Goldman Sachs/Citigroup/TD Cowen/Evercore ISI/Guggenheim Securities 23.5 19.00 20.00 $ 458.8 mil 6/18/2025 Wednesday S/O S/O
Read more

Last 100 IPOs - June 16, 2025

Number of IPOs priced : 100
Number Up: 58
Number Down: 39
Number Unchanged: 3
Percentage Change From Issue Price: 28.15%
Percentage Change for The Nasdaq Composite 35.22%

2025 IPO Scorecard - June 16, 2025

Number of IPOs priced (Excluding 54 units) : 104
Number Up: 59
Number Down: 42
Number Unchanged: 3
Total Return From Issue Price: 26.39%
The Nasdaq Composite Index YTD % Change 35.22%